Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTOR NASDAQ:ELDN NASDAQ:IMRX NASDAQ:TKNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$0.78-2.0%$0.81$0.49▼$6.19$72.53M3.4171,935 shs48,521 shsELDNEledon Pharmaceuticals$3.41-5.3%$3.55$1.35▼$4.60$263.21M0.94984,344 shs752,819 shsIMRXImmuneering$4.27-4.7%$5.28$1.66▼$10.08$276.26M0.382.07 million shs1.44 million shsTKNOAlpha Teknova$4.56-16.0%$3.57$1.91▼$6.68$244.48M0.63151,152 shs205,630 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology-2.00%-2.26%-14.22%-23.53%-16.87%ELDNEledon Pharmaceuticals-5.28%-10.50%-10.26%+22.66%+12.54%IMRXImmuneering-4.69%-26.00%-17.73%-19.89%+117.86%TKNOAlpha Teknova-16.02%-15.56%+25.27%+116.11%-21.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$0.78-2.0%$0.81$0.49▼$6.19$72.53M3.4171,935 shs48,521 shsELDNEledon Pharmaceuticals$3.41-5.3%$3.55$1.35▼$4.60$263.21M0.94984,344 shs752,819 shsIMRXImmuneering$4.27-4.7%$5.28$1.66▼$10.08$276.26M0.382.07 million shs1.44 million shsTKNOAlpha Teknova$4.56-16.0%$3.57$1.91▼$6.68$244.48M0.63151,152 shs205,630 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology-2.00%-2.26%-14.22%-23.53%-16.87%ELDNEledon Pharmaceuticals-5.28%-10.50%-10.26%+22.66%+12.54%IMRXImmuneering-4.69%-26.00%-17.73%-19.89%+117.86%TKNOAlpha Teknova-16.02%-15.56%+25.27%+116.11%-21.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTORCitius Oncology 2.33Hold$6.00669.23% UpsideELDNEledon Pharmaceuticals 2.40Hold$9.67183.48% UpsideIMRXImmuneering 2.86Moderate Buy$16.50286.42% UpsideTKNOAlpha Teknova 2.33Hold$8.0075.44% UpsideCurrent Analyst Ratings BreakdownLatest CTOR, IMRX, ELDN, and TKNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026IMRXImmuneering OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/19/2026IMRXImmuneering Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.004/20/2026TKNOAlpha Teknova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ELDNEledon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026IMRXImmuneering Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/9/2026IMRXImmuneering Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTORCitius OncologyN/AN/AN/AN/A$0.54 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.35 per shareN/AIMRXImmuneeringN/AN/AN/AN/A$3.38 per shareN/ATKNOAlpha Teknova$40.52M6.03N/AN/A$1.28 per share3.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTORCitius Oncology-$24.76M-$0.47N/AN/AN/AN/A-99.47%-42.16%8/18/2026 (Estimated)ELDNEledon Pharmaceuticals-$45.62M-$0.77N/AN/AN/AN/A-116.97%-41.91%8/13/2026 (Estimated)IMRXImmuneering-$56.03M-$1.17N/AN/AN/AN/A-31.93%-29.92%8/12/2026 (Estimated)TKNOAlpha Teknova-$17.26M-$0.32N/AN/AN/A-41.07%-24.32%-16.34%8/6/2026 (Estimated)Latest CTOR, IMRX, ELDN, and TKNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026CTORCitius Oncology-$0.01-$0.27-$0.26-$0.27$7.00 million$1.67 million5/15/2026Q1 2026IMRXImmuneering-$0.30-$0.21+$0.09-$0.21N/AN/A5/13/2026Q1 2026ELDNEledon Pharmaceuticals-$0.22-$0.33-$0.11-$0.33N/AN/A5/6/2026Q1 2026TKNOAlpha Teknova-$0.0926-$0.08+$0.0126-$0.08$10.23 million$11.08 million3/19/2026Q4 2025ELDNEledon Pharmaceuticals-$0.20-$0.10+$0.10-$0.10N/AN/A3/6/2026Q4 2025IMRXImmuneering-$0.31-$0.18+$0.13-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTORCitius OncologyN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTORCitius Oncology0.110.500.12ELDNEledon PharmaceuticalsN/A8.448.44IMRXImmuneeringN/A32.4532.45TKNOAlpha Teknova0.204.593.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTORCitius Oncology70.52%ELDNEledon Pharmaceuticals56.77%IMRXImmuneering67.65%TKNOAlpha Teknova13.81%Insider OwnershipCompanyInsider OwnershipCTORCitius Oncology7.80%ELDNEledon Pharmaceuticals12.30%IMRXImmuneering22.90%TKNOAlpha Teknova12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTORCitius OncologyN/A92.98 million85.73 millionN/AELDNEledon Pharmaceuticals1077.19 million67.69 millionOptionableIMRXImmuneering6064.70 million49.88 millionNot OptionableTKNOAlpha Teknova24053.61 million46.91 millionNot OptionableCTOR, IMRX, ELDN, and TKNO HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Arcus Biosciences (RCUS) and Tenaya Therapeutics (TNYA)June 4 at 6:35 PM | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO) and REPRO-MED Systems (KRMD)May 9, 2026 | theglobeandmail.comAlpha Teknova, Inc. (NASDAQ:TKNO) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 9, 2026 | finance.yahoo.comAlpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comAlpha Teknova Charts Cautious Path to 2027 GrowthMay 7, 2026 | tipranks.comAlpha Teknova Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comAlpha Teknova (TKNO) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comTeknova Reports First Quarter 2026 Financial ResultsMay 6, 2026 | globenewswire.comTeknova to Report First Quarter 2026 Financial Results on May 6, 2026April 22, 2026 | globenewswire.comFavourable Signals For Alpha Teknova: Numerous Insiders Acquired StockMarch 30, 2026 | finance.yahoo.comAlpha Teknova (NASDAQ:TKNO) CEO Acquires $55,900.00 in StockMarch 10, 2026 | insidertrades.comTeknova outlines 20%-25% long-term revenue growth target while investing $2M annually in commercial capabilitiesFebruary 27, 2026 | seekingalpha.comAlpha Teknova Inc (TKNO) Q4 2025 Earnings Call Highlights: Navigating Growth Amid ChallengesFebruary 27, 2026 | finance.yahoo.comAlpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call TranscriptFebruary 26, 2026 | seekingalpha.comTeknova Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 26, 2026 | globenewswire.comEarnings To Watch: Alpha Teknova Inc (TKNO) Reports Q4 2025 ResultFebruary 25, 2026 | finance.yahoo.comAlpha Teknova (TKNO): Investors are Waiting for Leading Indicators to Drive SalesFebruary 20, 2026 | insidermonkey.comTeknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026February 5, 2026 | globenewswire.comWhy Alpha Teknova, Inc.’s (TKNO) Stock Is Down 13.01%December 22, 2025 | aaii.comAAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Voyager Therapeutics (VYGR) and Terns Pharmaceuticals (TERN)November 13, 2025 | theglobeandmail.comAlpha Teknova, Inc. (NASDAQ:TKNO) Analysts Are Pretty Bullish On The Stock After Recent ResultsNovember 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAfter NVIDIA, Broadcom's Earnings Are Next—Here's What to WatchBy Leo Miller | May 26, 20263 Stocks Rallying on Micron's Price Boost: Substance or Hype?By Dan Schmidt | May 28, 2026The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000By Jeffrey Neal Johnson | May 12, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceBy Ryan Hasson | May 8, 2026CTOR, IMRX, ELDN, and TKNO Company DescriptionsCitius Oncology NASDAQ:CTOR$0.78 -0.02 (-2.00%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.78 0.00 (-0.51%) As of 06/5/2026 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Eledon Pharmaceuticals NASDAQ:ELDN$3.41 -0.19 (-5.28%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.49 +0.08 (+2.35%) As of 06/5/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Immuneering NASDAQ:IMRX$4.27 -0.21 (-4.69%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.26 -0.01 (-0.23%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Alpha Teknova NASDAQ:TKNO$4.56 -0.87 (-16.02%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.56 0.00 (0.00%) As of 06/5/2026 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
